ATE358487T1 - Kombination enthaltend cyamemazine und ein atypisches neuroleptikum - Google Patents

Kombination enthaltend cyamemazine und ein atypisches neuroleptikum

Info

Publication number
ATE358487T1
ATE358487T1 AT00988905T AT00988905T ATE358487T1 AT E358487 T1 ATE358487 T1 AT E358487T1 AT 00988905 T AT00988905 T AT 00988905T AT 00988905 T AT00988905 T AT 00988905T AT E358487 T1 ATE358487 T1 AT E358487T1
Authority
AT
Austria
Prior art keywords
cyamemazine
combination containing
atypical neuroleptic
neuroleptic
atypical
Prior art date
Application number
AT00988905T
Other languages
English (en)
Inventor
Michel Dib
Cyrille Leperlier
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE358487T1 publication Critical patent/ATE358487T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Containers Having Bodies Formed In One Piece (AREA)
  • Vehicle Interior And Exterior Ornaments, Soundproofing, And Insulation (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Compression Or Coding Systems Of Tv Signals (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Mechanical Pencils And Projecting And Retracting Systems Therefor, And Multi-System Writing Instruments (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT00988905T 1999-12-10 2000-12-08 Kombination enthaltend cyamemazine und ein atypisches neuroleptikum ATE358487T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9915632A FR2802101B1 (fr) 1999-12-10 1999-12-10 Association de cymemazine et d'un neuroleptique atypique

Publications (1)

Publication Number Publication Date
ATE358487T1 true ATE358487T1 (de) 2007-04-15

Family

ID=9553137

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00988905T ATE358487T1 (de) 1999-12-10 2000-12-08 Kombination enthaltend cyamemazine und ein atypisches neuroleptikum

Country Status (13)

Country Link
US (2) US6720318B2 (de)
EP (1) EP1239861B1 (de)
JP (1) JP5216176B2 (de)
AT (1) ATE358487T1 (de)
AU (1) AU2525201A (de)
CA (1) CA2393523C (de)
CY (1) CY1108053T1 (de)
DE (1) DE60034249T2 (de)
DK (1) DK1239861T3 (de)
ES (1) ES2283341T3 (de)
FR (1) FR2802101B1 (de)
PT (1) PT1239861E (de)
WO (1) WO2001041769A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE418987T1 (de) * 2003-02-07 2009-01-15 Aventis Pharma Inc Verwendung von 2-cyano-10- (2-methyl-3- (methylamino)- propyl)-phenothiazin oder einem pharmazeutisch akzeptablen salz davon als arzneimittel
FR2850871B1 (fr) 2003-02-07 2006-07-14 Aventis Pharma Sa Application du 2-cyano-10-(2-methyl-3-(methylamino)propyl) phenothiazine ou un sel pharmaceutiquement acceptable comme medicament
US20060217394A1 (en) * 2005-02-23 2006-09-28 Silvan S. Tomkins Institute, Inc. Treatment of anhedonia
FR2898271B1 (fr) * 2006-03-09 2009-01-16 Pierre Fabre Medicament Sa Nouvelle utilisation d'agents antihistaminiques pour le traitement preventif ou procede de syndromes inflammatoires, en particulier ceux declenches par les toga virus.
EP3310460B1 (de) 2015-06-16 2021-12-08 Basf Se Scr-katalysierter russfilter mit integriertem mager-nox-fallenkatalysator zur verwendung in der passiven selektiven katalytischen reduktion

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
GB9009229D0 (en) 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
DE4127737A1 (de) 1991-08-22 1993-02-25 Hoechst Ag Arzneimittel zur behandlung von abstossungsreaktionen bei organverpflanzungen
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
TW376319B (en) 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
FR2722099B1 (fr) * 1994-07-11 1996-10-04 Pf Medicament Nouveau produit de combinaison comprenant de la carpipramine et un neuroleptique.
EG24221A (en) 1995-03-24 2008-11-10 Lilly Co Eli Process for preparing olanzapine
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
ZA982368B (en) * 1997-03-27 1998-09-23 Akzo Nobel Nv New therapeutic combinations
IL123716A (en) * 1997-03-27 2001-03-19 Akzo Nobel Nv Therapeutic combinations of mirtazapine and an antipsychotic agent
UA73715C2 (en) 1997-09-30 2005-09-15 Lilly Co Eli Pharmaceutically acceptable formulation of olanzapine pamoate and its use for treatment
SK17492000A3 (sk) * 1998-05-29 2002-04-04 Eli Lilly And Company Liek na liečenie bipolárnych porúch a farmaceutický prostriedok

Also Published As

Publication number Publication date
FR2802101B1 (fr) 2003-02-28
CA2393523C (fr) 2010-11-02
WO2001041769A2 (fr) 2001-06-14
CY1108053T1 (el) 2013-09-04
JP5216176B2 (ja) 2013-06-19
CA2393523A1 (fr) 2001-06-14
DE60034249D1 (de) 2007-05-16
EP1239861B1 (de) 2007-04-04
US6982262B2 (en) 2006-01-03
AU2525201A (en) 2001-06-18
DE60034249T2 (de) 2007-12-20
WO2001041769A3 (fr) 2002-02-28
US20020183312A1 (en) 2002-12-05
PT1239861E (pt) 2007-06-21
JP2003516355A (ja) 2003-05-13
EP1239861A2 (de) 2002-09-18
US6720318B2 (en) 2004-04-13
DK1239861T3 (da) 2007-07-30
FR2802101A1 (fr) 2001-06-15
US20040167125A1 (en) 2004-08-26
ES2283341T3 (es) 2007-11-01

Similar Documents

Publication Publication Date Title
HK1068895A1 (en) Nitrogen-containing heterocyclic derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
IL152916A0 (en) Heteroaryl-phenyl heterobicyclic factor xa inhibitors
ATE340171T1 (de) Piperazinderivate zur behandlung bakterieller infektionen
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
DE60121988D1 (de) Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln
DE69925133D1 (de) Pyrrolobenzodiazepine
ZA200203316B (en) New use and novel n-azabicyclo-amide derivatives.
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
MXPA03007140A (es) Derivados de carbolina.
CL2004001174A1 (es) Composicion farmaceutica que comprende: 1-(4-fluorofenil)-3(r)-[3-(4-fluorofenil)-3(s)-hidroxipropil]-4(s)-(4-hidroxifenil)-2-acetidinona (ezetimiba) y excipientes; y su uso en el tratamiento y/o prevencion de aterosclerosis, hipercolesterolemia, dia
DE60001735D1 (de) 1-aminotriazolo 4,3-a chinazolin-5-one und/oder -thione inhibitoren von phosphodiesterasen iv
DK1736158T3 (da) Anvendel af 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazin samt de fysiologiske acceptable salte deraf
EE05281B1 (et) Fenofibraadi ja koensüüm Q10 kombinatsioon endoteeli düsfunktsiooni ravimiseks
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
ZA200309513B (en) Novel heterocyclic derivatives and medicinal use thereof.
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
MXPA03001826A (es) Derivados de arilpiperazina.
NO20012106D0 (no) Middel for behandling av benpatobolisme
DK1212119T3 (da) Anvendelse af cyamemazin ved behandling af brat seponering af benzodiazepiner
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
UA4614S (uk) Флакон під засіб для догляду за тілом
PT1273556E (pt) Estacao de tratamento simbiotico de aguas residuais.
GB9802542D0 (en) New use
NO20053247L (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1239861

Country of ref document: EP